Antidepressant dose matters for seniors with kidney trouble
NCT ID NCT07274241
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at over 12,000 older adults (age 66+) with low kidney function who started taking the antidepressant escitalopram. Researchers compared the safety of a 10 mg daily dose versus a 5 mg daily dose. The goal was to see if the higher dose led to more hospital visits, emergency department visits, or deaths within 30 days. The findings could help guide safer prescribing for this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Escitalopram (an antidepressant)
- What this could lead to
- If successful, this could help doctors choose safer antidepressant doses for older adults with kidney problems, reducing hospital visits and deaths.
- What could go wrong
- This is an observational study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
London Health Sciences Centre Research Institute
London, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Plastics in dialysis: could they add toxins to Children's blood?
- Can a newer heart failure drug protect kidneys better than an older one?
- Could a Pre-Surgery nerve block speed up recovery after hip fracture?
- A urine test strip that could transform kidney diet care?
- Iron deficiency hidden by inflammation: a new test may see through it
- AI model aims to predict heart risks after hip surgery in seniors